Pharmacokinetic/ Pharmacodynamics in Drug Development and Evaluation
Who should take these points in consideration ?
? efficacy both in short (efficacy) and long (emergence of resistance) terms this is what they already do at the research level …
2. Clinicians: more and more ? optimizing therapy now and protect the future but they often feel alone or insufficiently informed ...
3. Regulatory bodies ? to better appraise new drugs and set guidelines but they wish to be certain that this is the correct way !